Conatus Pharmaceuticals Inc (CNAT) Receives $8.67 Consensus PT from Brokerages

Share on StockTwits

Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have received a consensus rating of “Hold” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $8.50.

Several equities research analysts have recently issued reports on CNAT shares. Oppenheimer set a $10.00 price objective on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 6th. Stifel Nicolaus lowered shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research report on Thursday, December 6th. SunTrust Banks dropped their price objective on shares of Conatus Pharmaceuticals to $12.00 and set a “buy” rating for the company in a research report on Thursday, December 6th. ValuEngine lowered shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, December 11th. Finally, Zacks Investment Research lowered shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, December 17th.

Shares of Conatus Pharmaceuticals stock traded down $0.12 during trading hours on Friday, hitting $2.73. The company’s stock had a trading volume of 15,720 shares, compared to its average volume of 714,264. Conatus Pharmaceuticals has a 1-year low of $1.15 and a 1-year high of $6.74. The firm has a market capitalization of $83.37 million, a P/E ratio of -4.63 and a beta of 3.36.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative net margin of 53.62% and a negative return on equity of 82.49%. The company had revenue of $7.41 million during the quarter, compared to analyst estimates of $8.63 million. Sell-side analysts forecast that Conatus Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC boosted its stake in shares of Conatus Pharmaceuticals by 94.6% in the third quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 12,572 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in shares of Conatus Pharmaceuticals by 50.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 62,163 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 20,826 shares during the period. Creative Planning purchased a new position in shares of Conatus Pharmaceuticals in the fourth quarter valued at $38,000. Geode Capital Management LLC boosted its stake in shares of Conatus Pharmaceuticals by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 33,827 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Conatus Pharmaceuticals by 75.7% in the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after purchasing an additional 60,604 shares during the period. Institutional investors and hedge funds own 27.41% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Story: How To Calculate Debt-to-Equity Ratio

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitie Group PLC  Receives Consensus Recommendation of “Buy” from Brokerages
Mitie Group PLC Receives Consensus Recommendation of “Buy” from Brokerages
Critical Comparison: Weatherford International  versus Its Peers
Critical Comparison: Weatherford International versus Its Peers
Sanford C. Bernstein Analysts Give Beiersdorf  a €91.00 Price Target
Sanford C. Bernstein Analysts Give Beiersdorf a €91.00 Price Target
Wolverine World Wide  Downgraded by ValuEngine
Wolverine World Wide Downgraded by ValuEngine
Dycom Industries  Stock Rating Lowered by ValuEngine
Dycom Industries Stock Rating Lowered by ValuEngine
FY2020 EPS Estimates for Innergex Renewable Energy Inc  Lowered by Raymond James
FY2020 EPS Estimates for Innergex Renewable Energy Inc Lowered by Raymond James


© 2006-2019 Ticker Report